2.87
-0.07 (-2.38%)
| Penutupan Terdahulu | 2.94 |
| Jumlah Dagangan | 6,459 |
| Harga / Jualan (P/S) | 19.96 |
| Harga / Buku (P/B) | 1.17 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -7.95 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 177.45% |
| Nisbah Semasa (MRQ) | 2.11 |
| Aliran Tunai Operasi (OCF TTM) | -86.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -59.84 M |
| Pulangan Atas Aset (ROA TTM) | -28.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -1,556.28% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Seres Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.01% |
| % Dimiliki oleh Institusi | 35.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Flagship Pioneering, Llc | 30 Jun 2026 | 1,155,850 |
| Vontobel Holding Ltd. | 30 Jun 2026 | 122,975 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |